NCT00639769View on ClinicalTrials.gov

Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

May 31, 2007

Study Completion Date

July 31, 2008

Conditions
Head and Neck Cancer
Interventions
DRUG

cisplatin

Starting dose 30 mg/m2 Dose level -1 20 mg/m2

DRUG

irinotecan hydrochloride

50 mg/m2 IV over 60 minutes, plus Cisplatin 30mig/m2 IV, repeated weekly for two weeks. followed by a one-week rest. This 3-week schedule given two times to equal one 6-week cycle. Maximum of 6 cycles.

Trial Locations (8)

Unknown

Central Georgia Hematology Oncology Associates, P.C., Macon

Erlanger Health System, Chattanooga

Jackson-Madison County Hospital, Jackson

East Tennessee State University, Johnson City

Center for Biomedical Research, Knoxville

Meharry Medical College, Nashville

VA Tennessee Valley Healthcare Center, Nashville

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT00639769 - Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Biotech Hunter | Biotech Hunter